Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
I. Epilepsy: Current Concepts in Diagnosis and Treatment

Antiepileptic Drug Development Program

Roger J. Porter, M.D., James J. Cereghino, M.D., Gill D. Gladding, R.Ph., Bettiejean Hessie, B.S., Harvey J. Kupferberg, Ph.D., Barrett Scoville, M.D. and Billy G. White, Ph.D.
Cleveland Clinic Journal of Medicine June 1984, 51 (2) 293-305;
Roger J. Porter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James J. Cereghino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gill D. Gladding
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bettiejean Hessie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harvey J. Kupferberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barrett Scoville
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Billy G. White
Epilepsy Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The modern era of antiepileptic drug therapy began with the use of phenobarbital in 1912. In the years thereafter, many new drugs were introduced, including other barbiturates, hydantoins, succinimides, and oxazolidinediones. Then, for various reasons, the marketing of new antiepileptic drugs was dramatically curtailed. To help reverse this trend, the Epilepsy Branch of the National Institute of Neurological and Communicative Disorders and Stroke sponsored clinical trials of drugs which had already been marketed abroad, resulting in the distribution of clonazepam, carbamazepine, and valproic acid in the U.S. These trials were followed by the establishment of the Antiepileptic Drug Development Program, which encompasses both the preclinical and clinical elements of drug development, including the Anticonvulsant Screening Project, the Toxicology Project, and support for controlled clinical trials.

Index terms
  • Anticonvulsants
  • Epilepsy
  • Received October 1983.
  • Accepted October 1983.
  • Copyright © 1984 The Cleveland Clinic Foundation. All Rights Reserved.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 51 (2)
Cleveland Clinic Journal of Medicine
Vol. 51, Issue 2
20 Jun 1984
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antiepileptic Drug Development Program
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antiepileptic Drug Development Program
Roger J. Porter, James J. Cereghino, Gill D. Gladding, Bettiejean Hessie, Harvey J. Kupferberg, Barrett Scoville, Billy G. White
Cleveland Clinic Journal of Medicine Jun 1984, 51 (2) 293-305;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Antiepileptic Drug Development Program
Roger J. Porter, James J. Cereghino, Gill D. Gladding, Bettiejean Hessie, Harvey J. Kupferberg, Barrett Scoville, Billy G. White
Cleveland Clinic Journal of Medicine Jun 1984, 51 (2) 293-305;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Magnesium Deficiency-Dependent Audiogenic Seizures (MDDASs) in Adult Mice: A Nutritional Model for Discriminatory Screening of Anticonvulsant Drugs and Original Assessment of Neuroprotection Properties
  • Google Scholar

More in this TOC Section

I. Epilepsy: Current Concepts in Diagnosis and Treatment

  • Febrile convulsions: a new look at an old problem
  • Differential diagnosis and treatment of intractable seizures
Show more I. Epilepsy: Current Concepts in Diagnosis and Treatment

Contributions

  • Febrile convulsions: a new look at an old problem
  • Differential diagnosis and treatment of intractable seizures
  • Bipolar disorder: Current treatments and new strategies
Show more Contributions

Similar Articles

Keywords

  • Anticonvulsants
  • Epilepsy

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire